Heavy Metal Poisoning - Pipeline Review, H2 2020

September 2020 | 36 pages | ID: H5048C1F434EN
Global Markets Direct

Abstracts

Heavy Metal Poisoning - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heavy Metal Poisoning - Pipeline Review, H2 2020, provides an overview of the Heavy Metal Poisoning (Toxicology) pipeline landscape.
Heavy metal poisoning is the accumulation of heavy metals, in toxic amounts, in the soft tissues of the body. Sources of toxicity can include environmental, water supply, industrial and hobbies. Symptoms include headaches, drowsiness, confusion, seizures, nausea, vomiting, abdominal cramps, tinnitus, goiter, anorexia and diarrhea. Treatment includes chelation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Heavy Metal Poisoning - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Heavy Metal Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Heavy Metal Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Heavy Metal Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed and Preclinical stages are 1, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Heavy Metal Poisoning (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Heavy Metal Poisoning (Toxicology).
• The pipeline guide reviews pipeline therapeutics for Heavy Metal Poisoning (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Heavy Metal Poisoning (Toxicology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Heavy Metal Poisoning (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Heavy Metal Poisoning (Toxicology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Heavy Metal Poisoning (Toxicology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Heavy Metal Poisoning (Toxicology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Heavy Metal Poisoning - Overview
Heavy Metal Poisoning - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Heavy Metal Poisoning - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Heavy Metal Poisoning - Companies Involved in Therapeutics Development
Capture Pharmaceuticals Inc
EmeraMed Ltd
Medesis Pharma SA
PDX Pharmaceuticals LLC
ZoneOne Pharma Inc
Heavy Metal Poisoning - Drug Profiles
C-2E2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
deferoxamine mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emeramide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hinokitiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NU-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NU-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PDX-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Heavy Metal Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Heavy Metal Poisoning - Dormant Projects
Heavy Metal Poisoning - Discontinued Products
Heavy Metal Poisoning - Product Development Milestones
Featured News & Press Releases
Sep 21, 2018: President presents at the 2018 International Academy of Oral Medicine and Toxicology (IAOMT) symposium
Sep 21, 2018: President presents at the 2018 International Academy of Oral Medicine and Toxicology (IAOMT) symposium
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Heavy Metal Poisoning, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Heavy Metal Poisoning - Pipeline by Capture Pharmaceuticals Inc, H2 2020
Heavy Metal Poisoning - Pipeline by EmeraMed Ltd, H2 2020
Heavy Metal Poisoning - Pipeline by Medesis Pharma SA, H2 2020
Heavy Metal Poisoning - Pipeline by PDX Pharmaceuticals LLC, H2 2020
Heavy Metal Poisoning - Pipeline by ZoneOne Pharma Inc, H2 2020
Heavy Metal Poisoning - Dormant Projects, H2 2020
Heavy Metal Poisoning - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Heavy Metal Poisoning, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Capture Pharmaceuticals Inc
EmeraMed Ltd
Medesis Pharma SA
PDX Pharmaceuticals LLC
ZoneOne Pharma Inc